144 related articles for article (PubMed ID: 9292521)
1. A novel degradation pathway of tissue factor pathway inhibitor: incorporation into fibrin clot and degradation by thrombin.
Ohkura N; Enjyoji K; Kamikubo Y; Kato H
Blood; 1997 Sep; 90(5):1883-92. PubMed ID: 9292521
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation.
Ohkura N; Soe G; Kohno I; Kumeda K; Wada H; Kamikubo Y; Shiku H; Kato H
Blood Coagul Fibrinolysis; 1999 Sep; 10(6):309-19. PubMed ID: 10493212
[TBL] [Abstract][Full Text] [Related]
3. Tissue factor pathway inhibitor; its structure, function and clinical significance.
Kato H
Pol J Pharmacol; 1996; 48(1):67-72. PubMed ID: 9112630
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.
Chowdary P
Drugs; 2018 Jun; 78(9):881-890. PubMed ID: 29845491
[TBL] [Abstract][Full Text] [Related]
5. Bacterial expression, purification, and partial characterization of amino acids 94-155 of human tissue factor pathway inhibitor (TFPI) as an inhibitor of blood coagulation factor Xa.
Day KC; Welsch DJ
Thromb Res; 1992 Dec; 68(4-5):369-81. PubMed ID: 1290165
[TBL] [Abstract][Full Text] [Related]
6. Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor.
Puy C; Tucker EI; Matafonov A; Cheng Q; Zientek KD; Gailani D; Gruber A; McCarty OJ
Blood; 2015 Feb; 125(9):1488-96. PubMed ID: 25587039
[TBL] [Abstract][Full Text] [Related]
7. Receptor-mediated endocytosis of coagulation factor Xa requires cell surface-bound tissue factor pathway inhibitor.
Ho G; Toomey JR; Broze GJ; Schwartz AL
J Biol Chem; 1996 Apr; 271(16):9497-502. PubMed ID: 8621621
[TBL] [Abstract][Full Text] [Related]
8. Suppressive Role of Tissue Factor Pathway Inhibitor-α in Platelet-Dependent Fibrin Formation under Flow Is Restricted to Low Procoagulant Strength.
Thomassen S; Mastenbroek TG; Swieringa F; Winckers K; Feijge MAH; Schrijver R; Cosemans JMEM; Maroney SA; Mast AE; Hackeng TM; Heemskerk JWM
Thromb Haemost; 2018 Mar; 118(3):502-513. PubMed ID: 29452445
[TBL] [Abstract][Full Text] [Related]
9. Structure and biology of tissue factor pathway inhibitor.
Bajaj MS; Birktoft JJ; Steer SA; Bajaj SP
Thromb Haemost; 2001 Oct; 86(4):959-72. PubMed ID: 11686353
[TBL] [Abstract][Full Text] [Related]
10. An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma.
Abumiya T; Enjyoji K; Kokawa T; Kamikubo Y; Kato H
J Biochem; 1995 Jul; 118(1):178-82. PubMed ID: 8537308
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces.
Hamamoto T; Yamamoto M; Nordfang O; Petersen JG; Foster DC; Kisiel W
J Biol Chem; 1993 Apr; 268(12):8704-10. PubMed ID: 8473315
[TBL] [Abstract][Full Text] [Related]
12. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8.
Cunningham AC; Hasty KA; Enghild JJ; Mast AE
Biochem J; 2002 Oct; 367(Pt 2):451-8. PubMed ID: 12117418
[TBL] [Abstract][Full Text] [Related]
13. Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site.
Enjyoji K; Miyata T; Kamikubo Y; Kato H
Biochemistry; 1995 May; 34(17):5725-35. PubMed ID: 7727433
[TBL] [Abstract][Full Text] [Related]
14. Plasmatic tissue factor pathway inhibitor is a major determinant of clotting in factor VIII inhibited plasma or blood.
Knappe S; Gorczyca ME; Jilma B; Derhaschnig U; Hartmann R; Palige M; Scheiflinger F; Dockal M
Thromb Haemost; 2013 Mar; 109(3):450-7. PubMed ID: 23348798
[TBL] [Abstract][Full Text] [Related]
15. Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat.
Han X; Girard TJ; Baum P; Abendschein DR; Broze GJ
Arterioscler Thromb Vasc Biol; 1999 Oct; 19(10):2563-7. PubMed ID: 10521388
[TBL] [Abstract][Full Text] [Related]
16. Effect of depolymerized holothurian glycosaminoglycan (DHG) on tissue factor pathway inhibitor: in vitro and in vivo studies.
Nagase H; Enjyoji K; Kamikubo Y; Kitazato KT; Kitazato K; Saito H; Kato H
Thromb Haemost; 1997 Aug; 78(2):864-70. PubMed ID: 9268186
[TBL] [Abstract][Full Text] [Related]
17. Tissue factor and tissue factor pathway inhibitor in nasal mucosa and nasal secretions of chronic rhinosinusitis with nasal polyp.
Shimizu S; Ogawa T; Takezawa K; Tojima I; Kouzaki H; Shimizu T
Am J Rhinol Allergy; 2015; 29(4):235-42. PubMed ID: 26163243
[TBL] [Abstract][Full Text] [Related]
18. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.
Hilden I; Lauritzen B; Sørensen BB; Clausen JT; Jespersgaard C; Krogh BO; Bowler AN; Breinholt J; Gruhler A; Svensson LA; Petersen HH; Petersen LC; Balling KW; Hansen L; Hermit MB; Egebjerg T; Friederichsen B; Ezban M; Bjørn SE
Blood; 2012 Jun; 119(24):5871-8. PubMed ID: 22563084
[TBL] [Abstract][Full Text] [Related]
19. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor.
Sprecher CA; Kisiel W; Mathewes S; Foster DC
Proc Natl Acad Sci U S A; 1994 Apr; 91(8):3353-7. PubMed ID: 8159751
[TBL] [Abstract][Full Text] [Related]
20. Maintaining extraembryonic expression allows generation of mice with severe tissue factor pathway inhibitor deficiency.
Castillo MM; Yang Q; Zhan M; Pan AY; Lawlor MW; Mast AE; Sood R
Blood Adv; 2019 Feb; 3(3):489-498. PubMed ID: 30755437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
